LN-225030
Ivabradine , 155974-00-8
Update time: 2023-04-23
PRODUCT Properties
| Boiling point: | 626.9±55.0 °C(Predicted) |
| Density | 1.146±0.06 g/cm3(Predicted) |
| pka | 8.77±0.50(Predicted) |
Description and Uses
Ivabradine is a first selective and specific If inhibitor that was approved by EMEA in November for symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm. This is the first agent to lower heart rate by inhibiting the cardiac pacemaker If current. The compound was discovered and developed by Servier and is currently being marketed in Ireland.
RELATED PRODUCTS
![3-[3-[[[(7S)-3,4-DiMethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]Methyl]MethylaMino]propyl]-1,3-dihydro-7,8-diMethoxy-H-3-benzazepin-2-one](https://img.chemicalbook.com/CAS/GIF/1086026-31-4.gif)
3-[3-[[[(7S)-3,4-DiMethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]Methyl]MethylaMino]propyl]-1,3-dihydro-7,8-diMethoxy-H-3-benzazepin-2-one
1086026-31-4
1086026-31-4
Ivabradine Impurity 1 Hydrochloride
85175-52-6
85175-52-6
Dehydro Ivabradine Oxalate
1346558-08-4
1346558-08-4
![(R)-1-(3,4-dimethoxybicyclo[4.2.0]Octa-1,3,5-trien-7-yl)-N-methylmethanamine](https://img.chemicalbook.com/CAS/20200515/GIF/1132667-04-9.gif)
(R)-1-(3,4-dimethoxybicyclo[4.2.0]Octa-1,3,5-trien-7-yl)-N-methylmethanamine
1132667-04-9
1132667-04-9
Ivabradine IMpurity
1616710-50-9
1616710-50-9